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Tumor cell-released autophagosomes
(TRAPs) promote immunosuppression
through induction of M2-like macrophages
with increased expression of PD-L1
Zhi-Fa Wen1†, Hongxiang Liu1†, Rong Gao1†, Meng Zhou1, Jie Ma1, Yue Zhang1, Jinjin Zhao1, Yongqiang Chen1,
Tianyu Zhang1, Fang Huang1, Ning Pan1, Jinping Zhang2, Bernard A. Fox3, Hong-Ming Hu3* and Li-Xin Wang1*
Abstract
Background: Tumor-associated macrophages (TAMs) facilitate tumor progression via establishment of an
immunosuppressive tumor microenvironment (TME). However, it is poorly understood how tumor cells could
functionally modulate TAMs. Our previous work indicated that tumor cell-released autophagosomes (TRAPs), a
type of LC3-II+ double-membrane extracellular vesicles (EVs) was sufficient to suppress anti-tumor immune
responses by inducing IL-10-producing B cells and immune suppressive neutrophils. Here, we hypothesized
that TRAPs may participate in regulating macrophage polarization.
Methods: TRAPs isolated from multiple murine tumor cell lines and pleural effusions or ascites of cancer
patients were incubated with bone marrow-derived macrophages (BMDMs) and monocytes, respectively.
Cellular phenotypes were examined by flow cytometry, ELISA and quantitative PCR. TRAPs treated BMDMs
were tested for the ability to suppress T-cell proliferation in vitro, and for promotion of tumor growth in vivo.
Transwell chamber and neutralization antibodies were added to ascertain the inhibitory molecules expressed
on BMDMs exposed to TRAPs. Knockout mice were used to identify the receptors responsible for TRAPs-induced
BMDMs polarization and the signaling mechanism was examined by western blot. Autophagy-deficient tumors
were profiled for phenotypic changes of TAMs and IFN-γ secretion of T cells by flow cytometry. The phenotype of
monocytes from pleural effusions or ascites of cancer patients was assessed by flow cytometry.
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Results: TRAPs converted macrophages into an immunosuppressive M2-like phenotype characterized by the
expression of PD-L1 and IL-10. These macrophages inhibited the proliferation of both CD4+ and CD8+ T cells in
vitro, and promoted tumor growth mainly through PD-L1 in vivo. TRAPs-induced macrophage polarization was
dependent on TLR4-mediated MyD88-p38-STAT3 signaling. In vivo studies indicated that disruption of autophagosome
formation in B16F10 cells by silencing the autophagy gene Beclin1 resulted in a remarkable delay in tumor growth,
which was associated with reduced autophagosome secretion, TAMs reprogramming and enhanced T cell activation.
Moreover, the levels of LC3B+ EVs appeared to correlate significantly with up-regulation of PD-L1 and IL-10 in matched
monocytes from effusions or ascites of cancer patients, and TRAPs isolated from these samples could also polarize
monocytes to an M2-like phenotype with increased expression of PD-L1, CD163 and IL-10, decreased expression of
HLA-DR, and T cell-suppressive function.
Conclusions: These findings suggest the TRAPs-PD-L1 axis as a major driver of immunosuppression in the TME by
eliciting macrophage polarization towards an M2-like phenotype, and highlight the potential novel therapeutic
approach of simultaneously targeting autophagy and PD-L1.
Keywords: Tumor cell-released autophagosomes (TRAPs), TAMs, PD-L1, IL-10, MyD88, T cell, Tumor microenvironment
Background
Tumor-associated macrophages (TAMs) represent a
major constituent of the leukocytes infiltrate in the tumor
microenvironment (TME) where they mostly display
tumor-promoting functions by facilitating tumor prolifera-
tion and survival, angiogenesis, metastasis, as well as im-
mune suppression [1]. High infiltration of TAMs generally
predicts unfavorable prognosis for most human tumors
[2–8], with the exception of colorectal cancer [9]. TAMs
are phenotypically heterogeneous and functionally diverse
and form a continuous spectrum of polarization states,
unlike the oversimplified M1/M2 classification [10].
During tumor progression, TAMs are polarized from a
M1-like anti-tumor to a M2-like pro-tumor phenotype
[11], highlighting that reprogramming TAMs could be
employed as a rational cancer therapeutic strategy. TAMs
suppress immune responses through multiple mechanisms.
For instance, TAMs are capable of producing immunosup-
pressive mediators/cytokines (arginase and IL-10) [12, 13]
and expressing inhibitory molecules (PD-L1 and PD-L2)
[14, 15]. Tumor-derived soluble mediators such as chemo-
kines (CCL2, CCL5, CXCL12), colony-stimulating factor-1
(CSF-1), TGF-β, IL-10, prostaglandin E2 (PGE2) and me-
tabolites (lactate) likely contribute to the development of
TAMs with M2-like phenotype and tumor-promoting
properties [16]. Recent studies indicated that, in addition
to soluble factors, tumor-derived exosomes could also
modulate macrophage cytokine profile and phenotype
[17–21]. However, little is known about how TRAPs
affect macrophage polarization and function in vitro
and in vivo.
Autophagy is an evolutionarily conserved and tightly or-
chestrated intracellular catabolic process in which mis-
folded proteins or damaged organelles are sequestered in
autophagosomes and ultimately fuse to lysosomes for deg-
radation and recycling [22, 23]. In contrast to degradative
autophagy, secretory autophagy could bypass lysosome fu-
sion and exports a wide range of cytoplasmic substrates,
such as IL-1β, HMGB1, amyloid beta, microorganism and
autophagic vacuoles [24–26]. A recent study showed that,
during bacterial infection, lysozyme-containing autopha-
gosomes undergo fusion with the apical surface of Paneth
cells and secretion into the intestinal lumen [27]. Autoph-
agy is normally executed at a basal level, but is strongly
enhanced in established tumors under hypoxic stress and
nutrient deprivation [28]. Although the role of autophagy
in cancer is controversial, it is generally accepted that au-
tophagy prevents cancer development in pre-malignant le-
sions, but promotes advanced cancer growth [29]. Indeed,
a higher autophagic flux is associated with poor response
to chemotherapy and worse overall survival in melanoma
patients [30]. Whereas the functional consequence of au-
tophagy inhibition in tumor cells has been established, the
outcome of targeting autophagy in the TME, especially in
TAMs, is not fully defined.
Our previous studies have verified the effects of TRAPs
on the immunological functions of B cells and neutrophils.
TRAPs can be readily taken up by B cells, subsequently in-
duce IL-10 production, which potentially suppresses
T-cell proliferation and antitumor responses [31]. Treat-
ment of human neutrophils with TRAPs promoted the
generation of reactive oxygen species (ROS) through
macropinocytosis, contributing to the inhibition of T-cell
activation and proliferation in a ROS-dependent manner
[32]. In this study, we demonstrate that TRAPs are suffi-
cient to induce an M2-like phenotype in macrophages
characterized by increased expression of PD-L1 and IL-10
via a mechanism involving TLR4-MyD88-p38-STAT3 sig-
naling. TRAPs-induced macrophages are highly efficient
at inhibiting T cell proliferation and promoting tumor
growth mainly through PD-L1. The immunomodulatory
effects of cancer patients-derived TRAPs on human
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monocytes are also confirmed. In addition, the tumor-sup-
porting properties of endogenous TRAPs were further
demonstrated in vivo in autophagy-defective tumor
models. Overall, these findings uncover a crucial role of
TRAPs on induction of immunosuppressive TAMs.
Methods
Mice, cell lines and reagents
Wild-type (WT) C57BL/6 and BALB/c mice were pur-
chased from the Comparative Medicine Center of Yang-
zhou University (Yangzhou, China). TLR2 knockout
(KO), TLR4 KO, MyD88 KO and OT-I mice were pur-
chased from the Nanjing Biomedical Research Institute
of Nanjing University (Nanjing, China). PD-L1 KO mice
were purchased from The Jackson Laboratory (MMRRC
stock # 32234, Bar Harbor, USA). All animal experi-
ments were approved by the Animal Care and Use Com-
mittee of Southeast University.
4T1, B16F10, EL4 and Hepa 1–6 were cultured in RPMI
1640 (HyClone) supplemented with 10% FBS (Gibco),
0.05mM 2-ME (Gibco) and 50 μg/ml Gentamicin (Lonza).
Raw264.7 were cultured in complete DMEM (HyClone)
medium. B16F10 tumor cells stably transduced with
Beclin1-specific short hairpin RNA (shRNA)
(BECN1-KD B16F10) and scrambled shRNA (Ctrl-
B16F10) were generated previously. All cell lines were
detected for Mycoplasma every 2 weeks and were
negative prior to use.
LPS, Chloroquine diphosphate, Chlorophenol red-β-
D-galactopyranoside (CPRG), and Proteinase K were
purchased from Sigma (St. Louis, USA). SB203580 and
Stattic were purchased from MCE (Shanghai, China).
Recombinant Murine M-CSF, IFN-γ and IL-4 were pur-
chased from PeproTech (Rocky Hill, USA). CFSE was
purchased from Invitrogen.
Patients
This study was approved by the Ethics Committee for
Human Studies of Southeast University and per-
formed under protocol 2016ZDKYSB112. Peripheral
blood and malignant pleural effusions and ascites
were collected from patients with pathologically diagnosed
with multiple cancer types. The clinical pathological
characteristics of enrolled patients are presented in
(Additional file 1: Table S1).
TRAPs isolation and characterization
TRAPs were prepared from tumor cells as previously
described [33]. Briefly, cells culture supernatant was
centrifuged at 450 g for 7 min to get rid of dead cells
and debris. The supernatant was further centrifuged at
12000 g for 15 min to pellet TRAPs-containing large
extracellular vesicles (EVs). Subsequently, EVs were
washed twice with PBS consisting of 20 mM NH4Cl
plus 2.5 mM EDTA and TRAPs were isolated from EVs.
TRAPs were finally resuspended in PBS and total protein
concentration was measured using a BCA Protein Assay
Kit (Pierce) following the manufacturer’s instructions. For
isolation of TRAPs from B16F10 cells transfected with
GFP-LC3, GFP-LC3-marked autophagosomes were pulled
down by using sheep anti-mouse IgG Dynabeads (Invitro-
gen) in combination with mouse anti-GFP antibody
(Abcam) according to the manufacturer’s recommenda-
tions. For isolation of TRAPs from other tumor cell lines
and malignant pleural effusions and ascites of cancer pa-
tients, autophagosomes were pulled down by using
anti-biotin MicroBeads (Miltenyi) in combination with bi-
otinylated LC3B Rabbit mAb (Cell Signaling Technology).
For flow cytometry identification, TRAPs were stained
with rabbit anti-LC3B antibody (Sigma), followed by R-PE
conjugated anti-Rabbit IgG secondary antibody (protein-
tech), or stained with PE-LC3B mAb (Cell Signaling Tech-
nology). The purity and LC3-II content were verified by
flow cytometry and Western blot, respectively.
Transmission Electron microscopy
TRAPs samples for transmission electron microscopy
were prepared as previously described [31]. Briefly, the
samples were fixed in 2.5% glutaraldehyde, 100 mM so-
dium cacodylate, 0.064% picric acid, 0.1% ruthenium red
and 1.6% paraformaldehyde, then post-fixed with a mix-
ture of osmium tetroxide plus potassium ferricyanide
and finally embedded in Epon. A series of TRAPs images
were taken with a JEM-1011 (JEOL, Tokyo, Japan) trans-
mission electron microscope at 60 kV.
Primary macrophage isolation
Bone marrow-derived-macrophages (BMDMs) and Peri-
toneal macrophages were generated according to previ-
ous literature [34]. Briefly, Bone marrow cells from the
femurs and tibias were cultured in RPMI 1640 supple-
mented with 10% FBS, 50 μg/ml Gentamicin and 20 ng/
mlM-CSF. BM cells were adjusted to a concentration of
~ 1 × 106/ml and were added into 100 mm petri dishes.
On day 3, culture medium was discarded and the at-
tached cells were washed once with cold PBS, fresh
complete medium containing M-CSF was then added.
BMDMs were harvested on day 7 and used for sub-
sequent experiments. For peritoneal macrophages, 6
ml cold complete medium was injected into periton-
eal cavity and macrophages were harvested by peri-
toneal lavage. The cells were centrifuged at 400 g for
10 min and seeded in 24-well plates. Macrophages
were allowed to adhere for 2 h at 37 °C and the sus-
pension cells were washed extensively with warm
medium prior to use.
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ELISA
The concentration of IL-6, IL-1β, IL-12 p70 and IL-10
produced by mouse macrophages was detected by IL-6,
IL-1β, IL-12 p70 and IL-10 ELISA kits (eBioscience), re-
spectively, in accordance with manufacturer’s guidelines.
Human IL-10 and IFN-γ were measured by ELISA kits
(eBioscience).
Real-time quantitative PCR
Total RNA was extracted from macrophages using an
RNAprep pure Cell / Bacteria Kit (TIANGEN), and was
subsequently reverse transcribed into cDNA with Prime-
Script RT reagent Kit (Takara). qRT-PCR was then con-
ducted on the StepOnePlus Real-Time PCR System
(Applied Biosystems, Foster City, USA) with TB Green
Premix Ex Taq II (Takara). Primers were synthesised by
GenScript (Nanjing, China) and the sequences for each
gene were presented in (Additional file 1: Table S2).
Relative gene expression was calculated using the 2-ΔΔCt
method normalizing to GAPDH expression.
Western blot
The cells were lysed in RIPA lysis buffer (Millipore) con-
taining protease (Bimake) and phosphatase (Bimake) in-
hibitors. The samples were resolved by SDS-PAGE and
transferred to PVDF membrane after blocking, the
membranes were incubated with primary antibodies
overnight at 4 °C and then exposed to secondary anti-
bodies. Protein bands were visualized using West Femto
Substrate Trial Kit (Thermo Scientific). The primary
antibodies included anti-p38 MAPK (Cell Signaling
Technology), anti-phospho-p38 MAPK (Thr180/Tyr182)
(Cell Signaling Technology), anti-STAT3 (Abcam), anti-
phospho-STAT3 (Tyr705) (Abcam), anti-LC3B (Sigma),
anti-Beclin1 (proteintech), anti-β-Tubulin (Cell Signaling
Technology), and anti-GAPDH (proteintech). The sec-
ondary antibodies were goat anti-mouse IgG HRP (pro-
teintech) and goat anti-rabbit IgG HRP (proteintech).
Flow cytometry and antibodies
Single-cell suspensions were blocked with mouse FcR
blocking reagent (Miltenyi Biotec) for 10 min at 4 °C
prior to surface staining. Cell viability was assessed by
Fixable viability dye eFluor 520 (eBioscience) to exclude
dead cells. The following anti-mouse antibodies were
used: FITC-CD11b, PE-F4/80, APC-F4/80, FITC-CD45,
PerCP-eFluor 710-MHC Class II (I-A/I-E), PerCP-eFluor
710-CD3, FITC-CD3e, FITC-CD4, APC-CD4, APC-CD8a,
PE-PD-L2, PE-B7-H2, PE-B7-H3, PE-B7-H4, PE-TIM-4,
PE-VISTA from eBioscience; APC-CD206, PE-PD-L1,
APC-CD86, PE/Cy7 Ki-67 from Biolegend; V450-CD4,
BV510-CD8, PE-IFN-γ from BD. The following anti-hu-
man antibodies were used: PerCP-eFluor 710-CD3,
APC-CD4, APC-CD8a from eBioscience; FITC-CD14,
PE-PD-L1, APC-CD163, APC-CD86, FITC-HLA-DR, PE-
Cy7-CD163, PE-CD25, PE-IFN-γ from Biolegend; FITC-
CD8, PE-IL-10 from BD. For intracellular staining, cells
were fixed and permeabilized with the Fixation/
Permeabilization solution kit (BD). All flow cytometry
data was acquired on FACSCalibur or LSRFortessa (BD,
San Jose, USA) and analyzed by FlowJo V10 (TreeStar,
Ashland, USA).
In vitro T cell proliferation and activation assay
Mouse T cells were isolated from spleens using the Mouse
Pan T Kit (Invitrogen), labeled with carboxyfluorescein
succinimidyl ester (CFSE) (2 μM; Invitrogen), then were
plated in 48-well anti-CD3 (5 μg/ml; BD) coated plates
plus soluble anti-CD28 (1 μg/ml; BD) added to the
medium. According to protocol described previously [35],
BMDMs pretreated with TRAPs were added 3 h after T
cell activation at indicated ratios. Cells were cocultured
with or without neutralizing monoclonal antibodies
against PD-L1, IL-10 or rat IgG isotype control
(eBioscience). For transwell assay, TRAP-pretreated
macrophages and T cells were seeded in the top chamber
and bottom chamber of the transwell insert, respectively.
For antigen-specific T cell proliferation, TRAP-pretreated
macrophages were cocultured with CFSE labeled OT-I
splenocytes in the presence of OVA257–264 peptide (1 μg/
ml; GL Biochem). 72 h later, CD4+ and CD8+ T cell div-
ision was determined by flow cytometry. For human T cell
proliferation assay, peripheral blood mononuclear cells
(PBMCs) were isolated from healthy donors by Ficoll-
Paque PLUS (GE Healthcare), and CD14+ monocytes and
autologous CD3+ T cells were purified from PBMCs using
the Human monocyte isolation kit (Stemcell) and Human
CD3 Kit (Invitrogen), respectively. Subsequently, mono-
cytes were exposed to TRAPs derived from cancer pa-
tients for 72 h, and then cocultured with CFSE labeled
CD3+ T cells at a ratio of 1:3 in 96-well anti-CD3 (5 μg/
ml; BD) coated plates plus soluble anti-CD28 (1 μg/ml;
BD) for 5 d. For T cell activation assay, TRAP-pretreated
monocytes were incubated with autologous T cells at a ra-
tio of 1:3 in anti-CD3 (0.5 μg/ml; BD) coated plates for 20
h, CD25 expression of CD4+ and CD8+ T cells was exam-
ined by flow cytometry. Breferdin A plus monensin was
added during the last 8 h of culture, the frequency of
IFN-γ+ T cells was determined by intracellular staining.
In vivo tumor models
For melanoma models, 6–8-week-old female C57BL/6
mice were implanted subcutaneously into the right flank
with 5 × 105 BECN1-KD B16F10 cells or Ctrl-B16F10
cells. Tumor growth was measured using a caliper every
third day, and mice were euthanized when the area of
tumors reached 150 mm2. For co-injection experiments,
B16F10 cells (5 × 105) were mixed with 2.5 × 105 WT or
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PD-L1 KO BMDMs treated with or without TRAPs
from B16F10 cells, and then co-injected subcutaneously
into mice. To analyze tumor immune response, mice
were sacrificed 15–20 d after tumor cell inoculation.
Draining lymph nodes (dLNs) or spleens were processed
through a 70 μm cell strainer with syringe plungers. Tu-
mors were excised, minced, and enzymatically dissoci-
ated in DMEM containing Collagenase IV (1 mg/ml;
Sigma) and DNase I (20 U/ml; Sigma) in a shaking incu-
bator at 37 °C for 30 min. Cell suspensions were subse-
quently passed through a cell strainer. For ex vivo
functional assays, tumor samples were stimulated with
Cell Stimulation Cocktail (eBioscience) for 5 h.
Statistical analysis
Data are expressed as Mean ± SEM. Statistically signifi-
cance of differences was analyzed using GraphPad
Prism 7 (GraphPad Software, La Jolla, USA) by unpaired
Student’s t test, one-way ANOVA or two-way ANOVA.
Correlation coefficients and their significance were
calculated by two-tailed Spearman’s rank correlation. A P
value of < 0.05 is considered statistically significant.
Results
TRAPs polarize macrophages to M2-like phenotype in
vitro and in vivo
Similar to the characteristics of autophagosomes [22],
TRAPs from culture supernatant of the murine melan-
oma cell line B16F10 were found to possess a double
membrane structure with diameters ranging from 300 to
900 nm and express LC3-II (Additional file 2: Figure
S1a-c). To examine the interaction between TRAPs and
macrophages, TRAPs labeled with the green fluorescent
dye CFSE were incubated with bone-marrow-derived
macrophages. TRAPs uptake was observed as early as
30 min and increased thereafter by confocal microscopy
analysis (Fig. 1a).
In order to determine the phenotype of macrophages
after TRAPs treatment, flow cytometric analysis was
conducted to detect the expression of M1 (CD86,
Fig. 1 TRAPs polarize macrophages toward an M2-like phenotype in vitro and in vivo. a Confocal images of BMDMs treated with CFSE-labeled
TRAPs (green). After incubation with TRAPs (10 μg/ml) for 0.5 h, BMDMs were stained with PE-F4/80 antibody (red) and DAPI (blue). Scale bar,
10 μm. b Expression analysis of CD206, PD-L1, CD86 and MHC II by flow cytometry. BMDMs were stimulated with LPS (100 ng/ml) + IFN-γ (20 ng/ml),
IL-4 (20 ng/ml) or TRAPs (10 μg/ml) for 48, 48 or 72 h, respectively. c Flow cytometry analysis of PD-L2, B7-H2, B7-H3, B7-H4, Tim-4 and VISTA for
BMDMs after incubating with TRAPs for 48 h. d Expression analysis of NOS2 and Arg1 mRNA in BMDMs treated with TRAPs (10 μg/ml) for 6 h by
qRT-PCR. e ELISA detection of IL-1β, IL-6, IL-10 and IL-12p70 produced by BMDMs exposed to TRAPs (10 μg/ml) for 72 h. f-h Mice (n = 3) were
intraperitoneally injected with four different doses of TRAPs (0, 10, 30 and 100 μg) at day 0 and the phenotype of peritoneal macrophages was
analyzed at day 3. Expression of CD206 (f) and PD-L1 (g) on macrophages (F4/80+CD11b+) was determined by flow cytometry. h mRNA expression
level of IL-10 and Arg1 in purified macrophages was detected by qRT-PCR. Results are representative of three independent experiments.
*p < 0.05, **p < 0.01 and ***p < 0.001 by unpaired t test (d, f, g and h)
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MHC-II) and M2 (CD206) markers. TRAPs substan-
tially increased CD206 and slightly reduced MHC-II
expression, but failed to induce CD86 (Fig. 1b). TRAPs
also upregulated the expression of PD-L1 but not other
co-inhibitory ligands [10], including PD-L2, B7-H2, B7-
H3, B7-H4, TIM-4, and VISTA, on macrophages (Fig. 1c).
Furthermore, RT-PCR analysis showed that the represen-
tative M2 gene arginase-1 (Arg1), but not the M1 gene ni-
tric oxide synthase 2 (NOS2), was increased (Fig. 1d). In
addition, TRAPs-treated macrophages secreted very high
level of IL-10, low levels of IL-1β and IL-6, and no
IL-12p70 (Fig. 1e). TRAPs also acted in a dose-dependent
manner to induce the expression of PD-L1 and IL-10
(Additional file 2: Figure S2a and b).
In addition to bone-marrow-derived macrophages, the
macrophage cell line RAW264.7 cells as well as periton-
eal macrophages showed increased PD-L1 expression
and IL-10 production after TRAPs treatment (Additional
file 2: Figure S2c and d). TRAPs-induced PD-L1 and
IL-10 expression did not appear to be an isolated
phenomenon, as TRAPs from a variety of murine tumor
cell lines had similar effects on macrophages (Additional
file 2: Figure S2e and f).
To further examine whether TRAPs regulate macro-
phages polarization in vivo, TRAPs isolated from
B16F10 tumor cells were intraperitoneally injected into
C57BL/6 mice. Mice that received 10 μg TRAPs had in-
creased expression of CD206 and PD-L1, and elevated
Il10 and Arg1 transcripts in peritoneal macrophages
(Fig. 1f–h), consistent with our in vitro observations sug-
gesting that TRAPs are M2-like macrophage polarizers.
TRAPs-educated macrophages exert immunosuppressive
functions in vitro
To ascertain the functional activities of TRAPs-induced
macrophages, CFSE-labeled naive T cells were cocul-
tured with varying numbers of macrophages pretreated
with or without TRAPs in the presence of anti-CD3/
anti-CD28. Notably, TRAPs-treated macrophages, but
not control macrophages, inhibited CD4+ and CD8+ T
cell proliferation (Fig. 2a and Additional file 2: Figure
S3a). Suppression was partially dependent upon cell con-
tact, as TRAPs-exposed macrophages had reduced sup-
pressive activity on CD4+ and CD8+ T-cell proliferation
when separated from T cells by transwell (Fig. 2b).
Fig. 2 TRAPs exposed macrophages inhibit T cell proliferation via PD-L1 and IL-10. a-d Representative determination of T cell proliferation by
flow cytometry. a, b, d CFSE-labeled purified CD3+ T cells were activated by immobilized anti-CD3 plus soluble anti-CD28 mAb, and were either
cultured alone or cocultured with BMDMs pretreated with or without TRAPs at a ratio of 5:1 for 3 d. b A transwell chamber was used to separate
BMDMs from T cells. d BMDMs were cocultured with T cells in the presence of anti-PD-L1 mAb, anti-IL-10 mAb or control IgG. c BMDMs were left
untreated or pretreated with 10 μg/ml B16F10 TRAPs or B16F10-OVA TRAPs for 2 d, and loaded with OVA257–264 peptide SIINFEKL (1 μg/ml) for 2
h, washed, were then incubated with CFSE-labeled OT-I splenocytes for 3 d at a ratio of 1:20. Data are representative of three independent
experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 by unpaired t test (a-d)
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Macrophages treated with either OVA+-TRAPs or
OVA−-TRAPs were equally capable of abrogating OT-I T
cell proliferation induced by the cognate OVA257–264 pep-
tide, indicating that TRAPs-stimulated macrophages could
also inhibit antigen-specific CD8+ T cell proliferation
(Fig. 2c). PD-L1 blockade, and to a lesser extent, IL-10
neutralization, significantly restored T cell proliferation.
More importantly, dual PD-L1/IL-10 blockade com-
pletely abrogated the suppressive function of TRAPs-
treated macrophages on T cell proliferation (Fig. 2d).
Macrophages exposed to EL4 cell-derived TRAPs were
pulsed with OVA257–264 peptide and subsequently co-
cultured with the OVA257–264-specific B3Z hybridoma
cells which constitutively express a high level of PD-1.
TRAPs-treated macrophages were less efficient in acti-
vating B3Z cells than control macrophages. IL-10
blockade partially restored B3Z activation, and PD-L1
blockade even augmented the B3Z activation (Additional
file 2: Figure S3b). Taking together, the mechanism for
TRAPs-treated macrophages appeared to predominately
involve PD-L1/PD-1 signaling, with IL-10 playing a minor
role.
The immunosuppressive function of TRAPs-educated
macrophages is TLR4-MyD88-dependent
TRAPs are enriched of a broad array of endogenous
damage-associated molecular pattern molecules (DAMPs),
which may trigger innate immune responses through
TLRs [31]. Moreover, TLR ligation of antigen-presenting
cells (APCs) was critical for the induction of PD-L1 and
IL-10 [36]. To determine the mechanism of TRAPs-medi-
ated macrophage polarization, BMDMs from mice defi-
cient in TLR2, TLR4, or MyD88 were incubated with
TRAPs. TRAPs-induced PD-L1 expression was com-
pletely MyD88-dependent, and PD-L1 upregulation was
markedly diminished due to TLR4, but not TLR2 defi-
ciency (Fig. 3a). IL-10 secretion was impaired in Tlr4−/− or
Myd88−/− macrophages, although reduced IL-10 release
was also observed in Tlr2−/− macrophages (Fig. 3b).
In addition, Tlr4−/− or Myd88−/−, but not Tlr2−/− mac-
rophages treated with TRAPs had diminished capability
of inhibiting OT-I proliferation (Fig. 3c and d). Collect-
ively, these results indicate that TLR4-MyD88, but not
TLR2, underlies the suppressive function of TRAPs-edu-
cated macrophages on T cell proliferation.
p38-STAT3 signaling promotes TRAPs-mediated
macrophage polarization
We further clarified TRAPs-induced signals in macro-
phage polarization, and focused on the p38 pathway,
which was reported to have a pivotal role in the induc-
tion of PD-L1 and IL-10 [36] and IL-4-induced alterna-
tive activation of macrophages [37]. After stimulation of
BMDMs with TRAPs, p38 phosphorylation was observed
at 0.5 h, and declined rapidly after 1 h to the control
level at 4 h. Phosphorylation of STAT3 was detectable at
2 h, and increased thereafter (Fig. 4a). Next, we deter-
mined whether p38 was required for TRAPs-induced
STAT3 activation. Consistent with this hypothesis, inhib-
ition of p38 activation by the specific inhibitor SB203580
repressed STAT3 phosphorylation (Fig. 4b) and the in-
duction of PD-L1 and IL-10 (Fig. 4c and d). Pretreat-
ment of macrophages with the STAT3 inhibitor Stattic
also significantly diminished PD-L1 and IL-10 induction
(Fig. 4e and f). Treatment of TRAPs with proteinase K,
but not DNase or RNase, significantly blocked the
upregulation of PD-L1 and IL-10 (Fig. 4g and h).
Taken together, these findings indicate that macro-
phages polarization is induced by protein components
on TRAPs via activation of the p38-STAT3 pathway.
Inhibition of autophagy in tumor cells retards tumor
growth and enhances antitumor responses
To determine whether TRAPs favored the tumor-pro-
moting characteristics of TAMs, we established
B16F10 cells that stably express shRNA targeting the
central autophagy regulator Beclin1 [22] (Additional
file 2: Figure S4a). Beclin1 knockdown caused lower
intracellular LC3-II accumulation, blocked the enhance-
ment of LC3-II induced by chloroquine (Additional file 2:
Figure S4b), and reduced TRAPs secretion (Additional file
2: Figure S4c) in Beclin1 knockdown B16F10 cells. When
inoculated into C57BL/6 mice, Beclin1 knockdown cells
exhibited a significant delay of growth (Fig. 5a). Of note,
stable inhibition of autophagy in tumor cells in vivo was
confirmed over the duration of the study, as evidenced
by the reduction of Beclin1 and LC3-II in cell lysates of
tumors harvested around 20 days after implantation
(Additional file 2: Figure S4d). Meanwhile, TRAPs from
BECN1-KD B16F10 cells had reduced ability to induce
PD-L1 and IL-10 expression on BMDMs compared
with TRAPs from Ctrl-B16F10 cells (Additional file 2:
Figure S4e and f ).
We postulated that the low tumor burden caused by
Beclin1 silencing may be related to altered tumor im-
mune microenvironment, including the functional prop-
erties of TAMs. TAMs from mice bearing Beclin1
knockdown tumors had significantly decreased expres-
sion of CD206 and PD-L1, as well as slightly increased
expression of CD86 and MHC-II whereas the effect
did not achieve statistical significance (Fig. 5b), indi-
cating that loss of tumor cell autophagy led to
TAMs reprogramming from an immunosuppressive
to an inflammatory phenotype. Furthermore, a higher
frequency of IFN-γ-producing T cells was observed
in Beclin1 knockdown tumors. Re-stimulation of T
cells from spleens and dLNs also revealed a higher
proportion of IFN-γ+ CD4+ and CD8+ T cells in mice
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bearing Beclin1 knockdown tumors (Fig. 5c). Intratu-
moral and dLNs T cells in mice bearing Beclin1 tu-
mors expressed higher level of the proliferation
marker Ki-67 (Fig. 5d).
To further determine whether PD-L1 upregulation by
TRAPs-treated BMDMs could facilitate tumor growth,
B16F10 cells were co-injected with WT or PD-L1-defi-
cient (Pdcd1l1−/−) BMDMs treated with or without
TRAPs, respectively. Mice co-injected with Pdcd1l1−/−
BMDMs experienced slower tumor growth than WT
BMDMs with or without TRAPs pretreatment. Co-in-
jection of TRAPs-stimulated WT BMDMs signifi-
cantly accelerated tumor growth compared to the co-
injection of control WT BMDMs. Most importantly,
TRAPs treatment of WT but not Pdcd1l1−/− BMDMs
resulted in larger tumors as compared to the untreated
group (Fig. 5e). These results corroborate the conclu-
sion that TRAPs-educated macrophages rely on PD-L1
induction to dampen T-cell mediated antitumor im-
mune responses to foster tumor progression.
Fig. 3 Immunosuppression mediated by TRAPs treated BMDMs is dependent on TLR4-MyD88 signaling. a Expression analysis of PD-L1 by flow
cytometry. BMDMs derived from WT, TLR2−/−, TLR4−/−, or MyD88−/− mice were incubated with TRAPs (10 μg/ml) for 48 h. b ELISA detection of
IL-10 secreted from BMDMs exposed to TRAPs (10 μg/ml) for 72 h. c, d Detection of OT-I CD8+ T cell division by flow cytometry. BMDMs
derived from WT, TLR2−/−, TLR4−/−, or MyD88−/− mice were left untreated or pretreated with B16F10 TRAPs (10 μg/ml) for 2 d, and pulsed with
peptide SIINFEKL (1 μg/ml) for 2 h, washed, and followed by coculture with CFSE-labeled OT-I splenocytes for 3 d at a ratio of 1:20. Data
(mean ± SEM) are representative of three independent experiments. **p < 0.01, ***p < 0.001 by unpaired t test. (b and d)
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Autophagosomes from cancer patients induce monocyte
polarization to M2-like phenotype with
immunosuppressive activities
To further determine whether autophagosomes from
cancer patients contribute to the formation of immuno-
suppressive TAMs, 25 malignant pleural effusions or
ascites specimens were collected, and their clinical char-
acteristics were depicted in (Additional file 1: Table S1).
The samples contain abundant vesicles that were similar
in size, morphology and the expression of typical
markers to the previously described autophagosomes
isolated from cell culture supernatant (Additional file 2:
Figure S1d–f ). Elevation of CD163, PD-L1 and IL-10 ex-
pression on CD14+ monocytes from PBMCs of cancer
patients was observed as compared to those from
healthy donors (Fig. 6a–c). Moreover, the results showed
a significant positive correlation between the concentra-
tion of LC3B+ autophagosomes and the expression of
PD-L1 and IL-10 in matched monocytes from effusions
or ascites of cancer patients (Fig. 6d and e). Peripheral
blood CD14+ monocytes from healthy donors treated
with TRAPs from cancer patients exhibited a significant
increase in CD163 and PD-L1 expression and a decrease
in HLA-DR expression. TRAPs stimulation showed the
trend of downregulating CD86 expression, although the
effect did not achieve statistical significance (Fig. 6f and
g). Meanwhile, monocytes produced high level of IL-10
following TRAPs stimulation (Fig. 6h). Intriguingly, we
also found that LC3B+ EVs, isolated from malignant as-
cites of a lung cancer patient (Additional file 2: Figure
S6a), were more potent than LC3B− EVs to upregulate
CD163, PD-L1 and IL-10 expression and downregulate
HLA-DR expression of monocytes (Additional file 2: Fig-
ure S6b-d), suggesting that LC3B+ EVs (TRAPs) are a
dominant subtype of large EVs in converting monocytes.
To verify the immunoregulatory effects of TRAPs-
treated monocytes, we cultured these cells with CFSE-la-
beled autologous T cells in the presence of anti-CD3 and
anti-CD28. Consistent with our observations in mouse
BMDMs, TRAPs-activated monocytes acquired the abil-
ity to suppress the proliferation of both CD4+ and CD8+
T cells (Fig. 6i). Meanwhile, TRAPs-pretreated mono-
cytes suppressed the expression of CD25 on T cells (Fig.
6j), and diminished the frequency of IFN-γ+ T cells and
IFN-γ secretion into the supernatant (Fig. 6k). Collect-
ively, autophagosomes from malignant pleural effusions
or ascites of cancer patients were able to modulate
TAMs polarization toward an M2-like phenotype with
potent immunosuppressive functions.
Discussion
TAMs can be polarized into tumor-promoting pheno-
type with immune modulatory effects by tumor-derived
instructive signals within the TME, such as CSF-1 [38],
Fig. 4 p38-STAT3 signaling in BMDMs and protein fraction in TRAPs are essential for induction of PD-L1 and IL-10. a BMDMs were exposed to
TRAPs (10 μg/ml) at indicated time points. Cell lysates were analyzed for p38, p-p38, STAT3 and p-STAT3 by western blot. GAPDH was used as a
loading control. b BMDMs were pretreated with p38 inhibitor SB203580 (3 μM) for 1 h, and then co-incubated with TRAPs (10 μg/ml) for 4 h.
Expression of STAT3 and p-STAT3 was detected by western blot. c BMDMs were exposed to SB203580 at described concentrations for 1 h, and
followed by incubation with TRAPs (10 μg/ml) for 72 h. PD-L1 expression was determined by flow cytometry, and (d) the production of IL-10 was
assessed by ELISA. e BMDMs were pretreated with STAT3 inhibitor Stattic (1 and 3 μM) for 1 h, and then stimulated with TRAPs (10 μg/ml) for 72
h. PD-L1 expression and (f) IL-10 secretion was determined by flow cytometry and ELISA, respectively. g TRAPs were pretreated with Proteinase K
for 2 h at 55 °C, DNase I for 1 h at 37 °C or RNase for 3 h at 37 °C, respectively, followed by incubation with BMDMs for 72 h. PD-L1 was evaluated
by flow cytometry, and (h) IL-10 was tested by ELISA. Data are shown as mean ± SEM, and are representative of three independent experiments.
***p < 0.001 by unpaired t test. (d, f and h)
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Fig. 5 (See legend on next page.)
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lactate [39] and PGE2 [40]. Recently, extracellular vesi-
cles have also been shown to be associated with TAMs
polarization [41, 42]. In the present study, we observed
that (i) TRAPs from murine tumor cell lines as well as
malignant pleural effusions and ascites of cancer pa-
tients were internalized by macrophages and skewed
macrophages to an M2-like phenotype with increased
expression of PD-L1 and IL-10; (ii) blocking PD-L1 on
macrophages significantly abrogated TRAPs-mediated
inhibition of T cell proliferation and promotion of
tumor growth; (iii) TLR4-MyD88-p38-STAT3 signaling
pathway was instrumental for TRAPs-induced upregu-
lation of PD-L1 and IL-10 expression in macrophages;
(iv) interference with autophagosome formation in
tumor cells inhibited tumor growth and blocked M2-
like macrophage polarization. Our results revealed that
TRAPs are a novel type of EVs capable of conferring
pro-tumor properties to TAMs (Fig. 7).
During classical autophagy, autophagosomes fuse with
lysosomes to degrade cytoplasmic cargo. However, we
have shown an alternative destiny of the autophago-
somes, which is tumor cells release them to the extracel-
lular milieu through currently unknown mechanisms
[33]. Importantly, autophagosomes can serve as vehicles
to transfer a broad spectrum of contents, including
tumor antigens and DAMPs (HSPs, HMGB1, S100 pro-
teins, DNA and RNA) to different types of target cells.
Inhibition of the degradative function of proteasome and
lysosome, a wider repertoire of tumor-associated anti-
gens and DAMPs were enriched in autophagosomes.
These artificial autophagosomes, termed DRibble (DRiPs-
containing blebs), could be utilized as a potent cancer vac-
cine to efficiently activate innate and adaptive immune re-
sponses [33, 43]. Nevertheless, our observations also
suggest that naturally released autophagosomes, called
TRAPs, exert immune suppressive roles by regulating the
functions of B cells and neutrophils [31, 32]. Although re-
cent literatures emphasized the importance of exosomes
derived from chronic lymphocytic leukemia (CLL) and
glioblastoma in eliciting tumor-supportive TAMs [41, 42,
44], TRAPs described here are vesicles that are biochem-
ically and functionally distinct from exosomes. TRAPs are
300–900 nm sized double-membrane structure vesicles
that express the typical autophagosome marker LC3-II
but not the exosome marker CD63, and could be pelleted
at a low centrifugation speed (12,000 g). We also excluded
the interference of other extracellular vesicles, by purifying
TRAPs with LC3B magnetic beads.
Treatment of BMDMs with TRAPs induced mixed
M2-like macrophage polarization. In addition to IL-10,
TRAPs-induced BMDMs also produced significant levels
of proinflammatory cytokines, including IL-1β and IL-6,
but no IL-12. In fact, these two proinflammatory cyto-
kines were reported to be highly proangiogenic in the
TME and essential for tumor progression [45]. Intri-
guingly, we observed the upregulation of PD-L1 on mac-
rophages after treatment with TRAPs. Although tumor
cells were initially regarded as the predominant source
of PD-L1 for immune suppression, clinical trials showed
that cancer patients with PD-L1-negative tumors can
benefit from PD-1/PD-L1 blockade therapy, implying
the involvement of PD-L1 on host cells in this effect
[46]. Recently, emerging data indicated that PD-L1 on
myeloid cells, including DCs and macrophages, but not
on tumor cells, determined the response to PD-L1
blockade in mice [47, 48]. Furthermore, the percentage
of PD-L1+ macrophages correlated with the clinical effi-
cacy of PD-1/PD-L1 blockade in melanoma and ovarian
cancer. We found TRAPs-stimulated BMDMs could in-
hibit T-cell proliferation in response to the nonspecific
anti-CD3/CD28 stimulus and the specific OVA257–264
stimulus. PD-L1 had a major role in suppression, and
the simultaneous blockade of PD-L1 and IL-10 almost
completely restored T cell proliferation.
A growing body of research suggested that endogen-
ous TLRs ligands not only have immune stimulatory ef-
fects but also engender immune tolerance via the
induction of several immunosuppressive elements, such
as Tregs, PD-L1 and IL-10 [49]. Our data showed that
TLR4 was a key receptor for TRAPs-mediated macro-
phage signaling. TLR2 ablation only diminished the pro-
duction of IL-10, whereas TLR4 ablation led to the
reduction of both IL-10 and PD-L1. Importantly, the in-
duction of IL-10 and PD-L1 was almost completely ab-
rogated in Myd88−/− BMDMs. In line with this, MyD88
deficiency completely abolished TRAPs-treated BMDMs
(See figure on previous page.)
Fig. 5 Knockdown of Beclin1 inhibits tumor growth and alters TAMs polarization. a BECN1-KD B16F10 and Ctrl-B16F10 cells were s.c. implanted
to C57BL/6 mice (n = 6 per group). Tumor area was measured at the described days. b Tumor bearing mice were euthanized around day 15, total
TAMs (F4/80+ CD11b+) were gated and analyzed for mean fluorescent intensity (MFI) of CD206, PD-L1, CD86 and MHC II expression by flow
cytometry. Events are gated on singlet, live and CD45+ tumor infiltrating cells. c TILs were stimulated with Cell Stimulation Cocktail for 5 h, the
frequency of CD4+ IFN-γ+ and CD8+ IFN-γ+ T cells was determined by intracellular staining. Single suspension cells from dLNs and spleens were
stimulated with mitomycin C inactivated B16F10 cells at a ratio of 30:1 for 21 h, breferdin A plus monensin was added for the last 5 h of culture,
and IFN-γ production was determined by flow cytometry. d T cells from TILs, dLNs and spleens were tested for Ki-67 expression by intracellular
staining. e B16F10 cells were mixed with WT or PD-L1−/− BMDMs (2:1) treated with or without TRAPs and then injected s.c. to C57BL/6
mice (n = 6 per group). Tumor growth was monitored at the indicated days. Data (mean ± SEM) are representative of three independent
experiments. *p < 0.05 and ***p < 0.001 by unpaired t test (a-d) and two-way ANOVA (e)
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Fig. 6 TRAPs derived from malignant pleural effusions or ascites of cancer patients regulate monocytes polarization. a, b The MFIs of (a) CD163
and (b) PD-L1 on CD14+ monocytes from peripheral blood of cancer patients (CPs) (n = 14) and healthy donors (HDs) (n = 8) were assessed by
flow cytometry. c PBMCs from CPs and HDs were stimulated with LPS (100 ng/ml) for 18 h, breferdin A plus monensin was added for the last 6 h
of culture, and the frequency of CD14+ IL-10+ was determined by flow cytometry. d, e The graphs showed the correlation between concentration of
TRAP and MFI of PD-L1 on CD14+ monocytes and total IL-10 in malignant pleural effusions or ascites of cancer patients (n = 20). f-h Purified CD14+
monocytes from healthy donors were treated with TRAPs (5 μg/ml) derived from pleural effusions or ascites of cancer patients (n = 10) for 3 d. f, g The
expression of CD163, PD-L1, CD86 and HLA-DR was detected by flow cytometry. h The amount of IL-10 in the supernatant was assessed by ELISA. i
Analysis of T cell proliferation by flow cytometry. Monocytes were left untreated or pretreated with TRAPs for 3 d, then incubated with CFSE-labeled
autologous T cells (1:3) for 5 d in the presence of anti-CD3 and anti-CD28, or monocytes and T cells were separated by a transwell chamber. j, k
Monocytes were left untreated or pretreated with TRAPs from MDA-MB-231 cells (c-TRAP) and cancer patient (p-TRAP) for 3 d, then incubated with
autologous T cells (1:3) for 20 h in the presence of immobilized anti-CD3. j CD25 expression on T cells was examined by flow cytometry. k Breferdin A
plus monensin was added during the last 8 h of culture. The percentage of CD4+ IFN-γ+ and CD8+ IFN-γ+ T cells and total IFN-γ secretion in the
supernatant was detected by flow cytometry and ELISA, respectively. Data (mean ± SEM) are representative of three independent
experiments. *p < 0.05, **p < 0.01 and ***p < 0.001 by unpaired t test. (a, b, c, g, h and k) and Spearman’s rank correlation (d and e)
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mediated inhibition of T cell proliferation, whereas abla-
tion of TLR4 only partially restored T cell proliferation.
MAPKs have been considered as a major pathway in-
volved in TLR signaling. We found that PD-L1 and
IL-10 expression was partly attenuated after blocking
p38. Conversely, the inhibition of Erk1/2 or JNK had no
effect on the expression of PD-L1 (Additional file 2: Fig-
ure S5a). STAT3, a transcription regulator of M2 related
molecules [50], appeared critical in our system, as block-
ing of TRAPs-induced STAT3 activation impaired the
upregulation of IL-10 and PD-L1 on BMDMs. However,
there appeared no association between autocrine stimuli
and PD-L1 expression in our experimental settings, as
blocking IL-6 or IL-10, failed to decrease TRAPs-induced
PD-L1 expression (Additional file 2: Figure S5a), suggest-
ing that additional factors or cytokine-independent mech-
anisms were involved in the modulation of PD-L1.
Consistent with our observations, mounting evidences
have identified a decisive role for TLR4 signaling in direct
STAT3 activation and subsequent PD-L1 expression [50].
Future studies will explore whether other receptors or sig-
naling pathways are involved. An important question is
which components on TRAPs trigger TLRs and the down-
stream signaling. Pretreatment of TRAPs with proteinase
K, but not DNase or RNase, destroyed the stimulatory po-
tential of TRAPs, suggesting that the triggering ligands
are proteins. We previously showed that HMGB1 on
TRAPs was involved in inducing IL-10+ Bregs [31].
However, HMGB1 had no effect on the induction of
M2-like macrophages. Further studies are needed to
identify the determinants responsible for macrophage
polarization.
Although conflicting findings have been observed con-
cerning the role of autophagy in advanced cancer, autoph-
agy has been identified as a promising target in cancer
therapy. Autophagy inhibition not only impacts tumor cells
directly, but also may have antitumor effects by affecting
other constituents of the TME [51–53]. Indeed, we ob-
served that TRAPs secreted by Beclin1-silenced B16F10
cells contained less LC3-II and this correlated with reduced
ability to induce PD-L1 and IL-10. Intriguingly, TAMs iso-
lated from Beclin1 knockdown tumors displayed a less im-
munosuppressive phenotype with decreased levels of
CD206 and PD-L1. Furthermore, Beclin1 deficiency in
tumor cells boosted the functions of T cells as reflected by a
higher production of IFN-γ and higher percentage of Ki67+
TILs. This finding supports the model in which
Beclin1-dependent formation of TRAPs in B16F10 cells has
a crucial role in TAMs polarization. Conversely, melanomas
co-implanted with TRAPs-treated BMDMs had significant
tumor progression compared to tumors co-injected with
untreated BMDMs. Importantly, the tumor-promoting
Fig. 7 Proposed schematic model depicting the role of TRAPs in macrophage polarization and adaptive immune suppression. TRAPs are uptaken
by macrophages and promotes MyD88-p38-STAT3 activation via TLR4, leading to upregulation of PD-L1 and IL-10 that is responsible for inhibition of
cytotoxic T lymphocytes (CTLs) activation, and in turn enhancing tumor progression
Wen et al. Journal for ImmunoTherapy of Cancer           (2018) 6:151 Page 13 of 16
function of TRAPs-treated BMDMs in vivo was mainly
dependent on PD-L1.
Besides tumor cells, many other cell types were also found
in effusions and ascites, such as monocytes, DCs, T cells
[54]. Although we did not ascertain whether autophago-
somes are secreted exclusively by cancerous cells, we dem-
onstrated that LC3-II+ autophagosomes from malignant
pleural effusions or ascites of cancer patients were capable
of transforming human monocytes into those that signifi-
cantly suppress the proliferation and effector functions of T
cells. More importantly, we found TRAP was a dominant
subtype of large EVs in converting monocytes to a M2-like
phenotype, as reflected by elevated expression of CD163,
PD-L1, IL-10 and decreased expression of HLA-DR on
monocytes when compared with large LC3B− EVs. In
addition, PD-L1 and IL-10 expression in matched mono-
cytes, which were collected from effusions or ascites of can-
cer patients, was correlated with the levels of LC3B+ EVs in
the same cohort. Our studies provide new insight for the
role of TRAPs, a key subpopulation of large EVs, in the
tumor microenvironment that promotes the development
of PD-L1-high TAMs, and highlight that TRAPs could be
an important therapeutic target to reverse the immunosup-
pressive tumor microenvironment. Future studies will focus
on exploring the correlation between TRAP levels in per-
ipheral blood or ascites and the pathological characteristics
and disease progression of clinical cancer patients.
Conclusions
In this study, we demonstrate that TRAPs are a novel
mechanism exploited by tumor cells for immune suppres-
sion, including inducing M2 polarization as reflected by
increased expression of PD-L1 and IL-10. This effect is
mainly dependent on TLR4-mediated MyD88-p38-STAT3
signaling pathway. Blocking autophagy in tumor cells pro-
moted the switch of TAMs from immunosuppressive
M2-like to the antitumor M1-like phenotype and restored
immune function of TILs. These observations offer a
strong rationale for targeting autophagy as a therapeutic
approach to improve the efficacy of anti-PD-1 or anti-
PD-L1-based cancer immunotherapy.
Additional files
Additional file 1: Table S1. Clinical characteristics of 25 patients
presenting with malignant pleural effusions or ascites. Table S2.
Primers used in Real-time quantitative PCR analyses. (PDF 536 kb)
Additional file 2: Figure S1. Characterization of TRAPs from tumor
cell lines or cancer patients. Figure S2. Phenotype determination of
BMDMs stimulated by TRAPs with different doses and origin. Figure S3.
TRAPs treated BMDMs inhibit T cell proliferation. Figure S4. Genetic
inhibition of autophagy by targeting Beclin1 reduces TRAPs production.
Figure S5. TRAPs induced PD-L1 upregulation on BMDMs was mainly
dependent on p38 activation. Figure S6. Comparison of LC3B+ EVs and
LC3B- EVs in converting monocytes. (DOCX 1421 kb)
Abbreviations
APCs: Antigen-presenting cells; Arg1: Arginase 1; BMDMs: Bone marrow
derived macrophages; CFSE: Carboxyfluorescein succinimidyl ester; CLL: Chronic
lymphocytic leukemia; CPRG: Chlorophenol red-β-D-galactopyranoside;
CTLs: Cytotoxic T lymphocytes; DAMPs: Damage-associated molecular pattern
molecules; DCs: Dendritic cells; dLNs: Draining lymph nodes; Dribble: DRiPs-
containing blebs; EVs: Extracellular vesicles; HSP27: Heat shock protein 27;
KD: Knock down; KO: Knock out; mAb: Monoclonal antibody; NOS2: Nitric oxide
synthase 2; PBMC: Peripheral blood mononuclear cell; ROS: Reactive oxygen
species; shRNA: Short hairpin RNA; TAMs: Tumor-associated macrophages;
TEM: Transmission Electron Microscopy; TLRs: Toll-like receptors; TME: Tumor
microenvironment; TRAPs: Tumor cell-released autophagosomes; Treg: CD4+
regulatory T cells; WT: Wild-type
Acknowledgments
The authors would like to thank Dr. Yunlang Cai and Dr. Xilong Ou (Zhongda
Hospital, Medical School of Southeast University) for providing human
specimens. The authors thank Dr. Kang Chen (Wayne State University)
and Dr. Liwei Lu (The University of Hong Kong) for helpful discussion
and critical review of this manuscript.
Funding
This work was funded by grants from the National Natural Science Foundation
of China (31670918, 31370895, 31170857) to LXW, the Fundamental Research
Funds for the Central Universities and Research Innovation Program for College
Graduates of Jiangsu Province (KYLX_0193) to ZFW and China Scholarship
Council to ZFW.
Availability of data and materials
The datasets analyzed during the current study are available from the
corresponding author on reasonable request.
Authors’ contributions
ZFW, BAF, HMH and LXW designed the study. ZFW, HL, RG, MZ, JM, YZ, JZ,
YC, TZ, FH performed the experiments and collected the data. ZFW and LXW
prepared the figures. NP and JZ discussed the data. ZFW and LXW wrote the
manuscript. BAF and HMH contributed to manuscript editing. All authors
read and approved the final manuscript.
Ethics approval
All animal experiments were approved by the Animal Care and Use Committee
of Southeast University. All human experiments were approved by the Ethics
Committee for Human Studies of Southeast University and performed under
protocol 2016ZDKYSB112. Informed consent was obtained from all patients.
Consent for publication
All authors provide their consent for publication of the manuscript.
Competing interests
Hong-Ming Hu and Bernard A. Fox are co-founders of UbiVac. The other
authors declare no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Department of Microbiology and Immunology, Medical School of Southeast
University, 87 Dingjiaqiao Rd, Nanjing 210009, People’s Republic of China.
2Institutes of Biology and Medical Sciences, Soochow University, Suzhou
215123, People’s Republic of China. 3Robert W. Franz Cancer Research
Center, Earle A. Chiles Research Institute, Providence Portland Medical Center,
2N81 North Pavilion, 4805 N.E. Glisan St, Portland, OR 97213, USA.
Received: 20 July 2018 Accepted: 16 November 2018
References
1. Guerriero JL. Macrophages: the road less traveled, changing anticancer
therapy. Trends Mol Med. 2018;24:472–89.
Wen et al. Journal for ImmunoTherapy of Cancer           (2018) 6:151 Page 14 of 16
2. Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, et al. Quantitative
analysis of immune infiltrates in primary melanoma. Cancer Immunol Res.
2018;6:481–93.
3. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, et
al. Proliferating macrophages associated with high grade, hormone receptor
negative breast cancer and poor clinical outcome. Breast Cancer Res Treat.
2011;128:703–11.
4. Osinsky S, Bubnovskaya L, Ganusevich I, Kovelskaya A, Gumenyuk L,
Olijnichenko G, et al. Hypoxia, tumour-associated macrophages,
microvessel density, VEGF and matrix metalloproteinases in human
gastric cancer: interaction and impact on survival. Clin Transl Oncol.
2011;13:133–8.
5. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M. Detection of
M2 macrophages and colony-stimulating factor 1 expression in serous and
mucinous ovarian epithelial tumors. Pathol Int. 2009;59:300–5.
6. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic
value of tumor-associated macrophage count in human bladder cancer. Int
J Urol. 2000;7:263–9.
7. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density
of tumor-associated macrophages is associated with decreased survival in
advanced thyroid cancer. Endocr Relat Cancer. 2008;15:1069–74.
8. Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, et al. Dual
prognostic significance of tumour-associated macrophages in human
pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut.
2016;65:1710–20.
9. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High
macrophage infiltration along the tumor front correlates with improved
survival in colon cancer. Clin Cancer Res. 2007;13:1472–9.
10. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages:
functional diversity, clinical significance, and open questions. Semin
Immunopathol. 2013;35:585–600.
11. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor
progression: regulation by distinct molecular mechanisms. J Immunol. 2008;
180:2011–7.
12. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of
the immune system. Nat Rev Immunol. 2009;9:162–74.
13. Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, et al.
Macrophage IL-10 blocks CD8+ T cell-dependent responses to
chemotherapy by suppressing IL-12 expression in intratumoral
dendritic cells. Cancer Cell. 2014;26:623–37.
14. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, et al. Activated
monocytes in peritumoral stroma of hepatocellular carcinoma foster
immune privilege and disease progression through PD-L1. J Exp Med.
2009;206:1327–37.
15. Huber S, Hoffmann R, Muskens F, Voehringer D. Alternatively activated
macrophages inhibit T-cell proliferation by Stat6-dependent expression of
PD-L2. Blood. 2010;116:3311–20.
16. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated
macrophages as treatment targets in oncology. Nat Rev Clin Oncol.
2017;14:399–416.
17. Gärtner K, Battke C, Dünzkofer J, Hüls C, von Neubeck B, Kellner MK, et al.
Tumor-derived extracellular vesicles activate primary monocytes. Cancer
Med. 2018;7:2013–20.
18. Popēna I, Ābols A, Saulīte L, Pleiko K, Zandberga E, Jēkabsons K, et al. Effect
of colorectal cancer-derived extracellular vesicles on the immunophenotype
and cytokine secretion profile of monocytes and macrophages. Cell
Commun Signal. 2018;16:17.
19. Shinohara H, Kuranaga Y, Kumazaki M, Sugito N, Yoshikawa Y, Takai T, et al.
Regulated polarization of tumor-associated macrophages by miR-145 via
colorectal Cancer-derived extracellular vesicles. J Immunol. 2017;199:1505–15.
20. Hsu YL, Hung JY, Chang WA, Jian SF, Lin YS, Pan YC, et al. Hypoxic lung-
Cancer-derived extracellular vesicle MicroRNA-103a increases the oncogenic
effects of macrophages by targeting PTEN. Mol Ther. 2018;26:568–81.
21. Wang F, Li B, Wei Y, Zhao Y, Wang L, Zhang P, et al. Tumor-derived
exosomes induce PD1+ macrophage population in human gastric cancer
that promotes disease progression. Oncogene. 2018;7:41.
22. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms
and biological functions of autophagy. Dev Cell. 2004;6:463–77.
23. Nakatogawa H, Suzuki K, Kamada Y, Ohsumi Y. Dynamics and diversity in
autophagy mechanisms: lessons from yeast. Nat Rev Mol Cell Biol. 2009;
10:458–67.
24. Jiang S, Dupont N, Castillo EF, Deretic V. Secretory versus degradative
autophagy: unconventional secretion of inflammatory mediators. J Innate
Immun. 2013;5:471–9.
25. Ponpuak M, Mandell MA, Kimura T, Chauhan S, Cleyrat C, Deretic V.
Secretory autophagy. Curr Opin Cell Biol. 2015;35:106–16.
26. Minakaki G, Menges S, Kittel A, Emmanouilidou E, Schaeffner I, Barkovits K,
et al. Autophagy inhibition promotes SNCA/alpha-synuclein release and
transfer via extracellular vesicles with a hybrid autophagosome-exosome-
like phenotype. Autophagy. 2018;14:98–119.
27. Bel S, Pendse M, Wang Y, Li Y, Ruhn KA, Hassell B, et al. Paneth cells secrete
lysozyme via secretory autophagy during bacterial infection of the intestine.
Science. 2017;357:1047–52.
28. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress
response. Mol Cell. 2010;40:280–93.
29. Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, Maiuri MC, et al. Anti- and
pro-tumor functions of autophagy. Biochim Biophys Acta. 2009;1793:1524–32.
30. Ma XH, Piao S, Wang D, McAfee QW, Nathanson KL, Lum JJ, et al.
Measurements of tumor cell autophagy predict invasiveness, resistance to
chemotherapy, and survival in melanoma. Clin Cancer Res. 2011;17:3478–89.
31. Zhou M, Wen Z, Cheng F, Ma J, Li W, Ren H, et al. Tumor-released
autophagosomes induce IL-10-producing B cells with suppressive
activity on T lymphocytes via TLR2-MyD88-NF-kappaB signal pathway.
Oncoimmunology. 2016;5:e1180485.
32. Gao R, Ma J, Wen Z, Yang P, Zhao J, Xue M, et al. Tumor cell-released
autophagosomes (TRAP) enhance apoptosis and immunosuppressive
functions of neutrophils. Oncoimmunology. 2018;7:e1438108.
33. Li Y, Wang LX, Yang G, Hao F, Urba WJ, Hu HM. Efficient cross-presentation
depends on autophagy in tumor cells. Cancer Res. 2008;68:6889–95.
34. Zhang X, Goncalves R, Mosser DM. The isolation and characterization of
murine macrophages. Curr Protoc Immunol. 2008;Chapter 14:Unit 14 1.
35. Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG,
et al. Macrophage expression of hypoxia-inducible factor-1 alpha
suppresses T-cell function and promotes tumor progression. Cancer Res.
2010;70:7465–75.
36. Wolfle SJ, Strebovsky J, Bartz H, Sahr A, Arnold C, Kaiser C, et al. PD-L1 expression
on tolerogenic APCs is controlled by STAT-3. Eur J Immunol. 2011;41:413–24.
37. Jimenez-Garcia L, Herranz S, Luque A, Hortelano S. Critical role of p38 MAPK
in IL-4-induced alternative activation of peritoneal macrophages. Eur J
Immunol. 2015;45:273–86.
38. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1
promotes progression of mammary tumors to malignancy. J Exp Med.
2001;193:727–40.
39. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al.
Functional polarization of tumour-associated macrophages by tumour-
derived lactic acid. Nature. 2014;513:559–63.
40. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH,
Gorter A, Welters MJ, et al. M2 macrophages induced by prostaglandin E2
and IL-6 from cervical carcinoma are switched to activated M1
macrophages by CD4+ Th1 cells. J Immunol. 2011;187:1157–65.
41. Haderk F, Schulz R, Iskar M, Cid LL, Worst T, Willmund KV, et al. Tumor-
derived exosomes modulate PD-L1 expression in monocytes. Sci
Immunol. 2017;2:eaah5509.
42. Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, et al.
Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-
L1 expression on human monocytes. Oncoimmunology. 2018;7:e1412909.
43. Xing Y, Cao R, Hu HM. TLR and NLRP3 inflammasome-dependent innate
immune responses to tumor-derived autophagosomes (DRibbles). Cell
Death Dis. 2016;7:e2322.
44. de Vrij J, Maas SL, Kwappenberg KM, Schnoor R, Kleijn A, Dekker L, et al.
Glioblastoma-derived extracellular vesicles modify the phenotype of
monocytic cells. Int J Cancer. 2015;137:1630–42.
45. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship
to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8:887–99.
46. Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1
checkpoint. Immunity. 2018;48:434–52.
47. Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, et al. PD-L1 on
host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin
Invest. 2018;128:580–8.
48. Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, et al. Host expression of
PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor
regression. J Clin Invest. 2018;128:805–15.
Wen et al. Journal for ImmunoTherapy of Cancer           (2018) 6:151 Page 15 of 16
49. Ridnour LA, Cheng RY, Switzer CH, Heinecke JL, Ambs S, Glynn S, et al.
Molecular pathways: toll-like receptors in the tumor microenvironment--poor
prognosis or new therapeutic opportunity. Clin Cancer Res. 2013;19:1340–6.
50. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in
cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;
14:736–46.
51. Rybstein MD, Bravo-San Pedro JM, Kroemer G, Galluzzi L. The autophagic
network and cancer. Nat Cell Biol. 2018;20:243–51.
52. Yang A, Herter-Sprie G, Zhang H, Lin EY, Biancur D, Wang X, et al. Autophagy
sustains pancreatic Cancer growth through both cell-autonomous and
nonautonomous mechanisms. Cancer Discov. 2018;8:276–87.
53. Mgrditchian T, Arakelian T, Paggetti J, Noman MZ, Viry E, Moussay E, et al.
Targeting autophagy inhibits melanoma growth by enhancing NK cells
infiltration in a CCL5-dependent manner. Proc Natl Acad Sci U S A. 2017;
114:E9271–E9.
54. Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the
leukocyte infiltrate in ovarian cancer and its relationship to the expression
of C-C chemokines. Am J Pathol. 1997;150:1723–34.
Wen et al. Journal for ImmunoTherapy of Cancer           (2018) 6:151 Page 16 of 16
